Airway inflammation and bronchoconstriction — Drug Target

All drugs that target Airway inflammation and bronchoconstriction — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Combination inhaler (ICS/LAMA/LABA)

Marketed (1)

• Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) · Thammasat University · Combination inhaler (ICS/LAMA/LABA) · Respiratory
  FUV is a triple-combination inhaler that integrates a corticosteroid (fluticasone furoate), a long-acting muscarinic antagonist (umeclidinium), and a long-acting beta2-adrenergic agonist (vilanterol) to provide synergistic bronchodilation and anti-inflammatory effects.